• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Moderna stock rises 8%: can it continue its cancer vaccine success rally?

by September 17, 2026
written by September 17, 2026

Moderna (MRNA) stock continued to rise on Thursday as investors assessed positive late-stage results for the company’s personalised mRNA cancer vaccine and a series of analyst upgrades and higher price targets.

The main catalyst has been the Phase 3 success of intismeran autogene, Moderna’s personalised mRNA cancer vaccine being developed with Merck’s Keytruda.

The treatment significantly reduced the risk of melanoma recurrence or death compared with Keytruda alone in patients with high-risk melanoma.

The results have led to a sharp reassessment of Moderna’s prospects as the company seeks to expand beyond its COVID-19 vaccine business.

Moderna’s cancer vaccine delivers Phase 3 success

The latest rally follows results from the Phase 3 INTerpath-001 trial, announced by Moderna and Merck on August 19.

The trial involved more than 1,100 patients with high-risk melanoma and compared the combination of intismeran autogene and Keytruda with Keytruda alone.

The combination significantly improved recurrence-free survival, according to the results.

The readout was described as the first positive Phase 3 result for a personalised mRNA cancer vaccine.

The treatment is designed individually for each patient using mutations identified in their tumour.

The companies said no new safety concerns emerged from the trial.

Moderna and Merck are continuing a broader clinical programme covering nine trials across melanoma, lung, bladder and kidney cancers.

The positive results have contributed to a sharp increase in Moderna shares.

The stock has gained more than 100% over the past month.

Analysts raise Moderna price targets

Several Wall Street firms have raised their expectations for Moderna following the cancer vaccine results.

Argus Research upgraded the stock to Buy and set a $180 price target on August 28.

Rothschild & Co, meanwhile, cut its rating to Sell on September 3 but raised its price target to $81.

Wolfe Research lifted its rating to Peer Perform on August 25.

The analyst moves reflect differing views on how much of the company’s potential cancer opportunity is already reflected in its share price.

Moderna’s consensus rating remains Hold, with an average price target of $91.

Evercore ISI also maintains a Hold rating, while Rothschild & Co Redburn has a Sell rating.

Argus’s $180 target followed its earlier upgrade to Buy, which came alongside the FDA’s approval of Moderna’s updated 2026-2027 COVID-19 vaccines.

Moderna leads healthcare momentum

Moderna’s rally has also placed it among the strongest-performing large and mega-cap US healthcare stocks.

According to Seeking Alpha’s Quant Momentum Grade, which compares momentum indicators against sector peers, Moderna has an A+ Momentum Grade. The stock has gained 393.79% year to date.

The sharp move highlights the changing market narrative around Moderna as investors assess its potential beyond COVID-19 vaccines.

The company’s personalised cancer vaccine programme provides a new potential growth area, while its broader clinical programme could expand the opportunity across several cancer types.

The post Moderna stock rises 8%: can it continue its cancer vaccine success rally? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
King Charles sounds AI alarm as Huang, Hassabis gather for private summit
next post
Why is Oracle stock gaining 4% today?

related articles

Anthropic’s ANT closes at $97.17, up 17% on...

November 19, 2026

Evening digest: Anthropic makes historic debut, AMD falls...

November 19, 2026

Nvidia stock falls for sixth day as Anthropic...

November 19, 2026

Aswath Damodaran values Anthropic at $76 a share,...

November 19, 2026

Anthropic pops 34% to cross $2 trillion valuation...

November 19, 2026

Anthropic CEO Dario Amodei defends $900B AI spending...

November 19, 2026

Temu owner just cut its marketing bill: stock...

November 19, 2026

Best Trading Platforms to Buy Anthropic Stock (ANT)

November 19, 2026

AMD stock falls 7% as Hunterbrook alleges links...

November 19, 2026

Anthropic IPO: How much could ANT stock rise...

November 19, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Scramble for Karoline Leavitt’s replacement ensues with just weeks until Trump’s spokesperson exits

    August 14, 2026
  • Nvidia controversy may mean more to Alibaba stock than investors realize

    November 12, 2026
  • Hochul remains defiant after sheriffs sue over law banning cooperation with ICE: ‘Bring it on’

    August 26, 2026
  • Morgan Stanley predicts this event to be the final stage of market correction

    November 18, 2026
  • Congress eyes rare bipartisan housing win with or without Trump’s help

    June 30, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Intel, AMD stocks slide again in aftermath of Broadcom’s weak outlook

    June 5, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,663)
  • Stock (90)

Latest Posts

  • Tesla stock slips 2% as SpaceX continues to climb: what’s hurting the EV giant

    June 16, 2026
  • Cathie Wood dumped $73 million of AMD and bought Nvidia stock: here’s why

    September 4, 2026
  • Bloom Energy stock surges 8% as S&P 500 inclusion boosts investor interest

    September 8, 2026

Recent Posts

  • Broadcom stock is in a local bear market: will it retest its record high?

    July 9, 2026
  • Can Anthropic IPO beat SpaceX to become the world’s largest?

    November 18, 2026
  • Why are Samsung and SK Hynix stocks surging after South Korea’s market crash?

    November 9, 2026

Editor’s Pick

  • Why Cathie Wood is doubling down on this $18 stock

    July 3, 2026
  • Trump’s grip on GOP faces fresh challenge in South Carolina governor battle

    June 9, 2026
  • FTSE edges higher as retail and financial stocks lift London markets

    June 25, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock